

## Former Fred Hutch Tech Transfer V.P. Joins Seattle Cancer-Fighting Startup SEngine Precision Medicine as Chief Business Officer

*Ulrich Mueller successfully led Fred Hutch spinouts such as Juno Therapeutics, Adaptive Biotechnologies, Presage Biosciences, Blaze Bioscience and Faraday Pharmaceuticals*

**SEATTLE, November 1, 2017** – Ulrich Mueller begins driving business development, licensing and corporate growth at SEngine Precision Medicine™ ([SEnginemedicine.com](http://SEnginemedicine.com)) on the 1<sup>st</sup> of November.

SEngine Precision Medicine has engineered an innovative, approved and patient-ready approach to identify and develop the next generation of cancer targeted drugs. SEngine strives to fulfill the promise of personalized medicine by providing cancer patients with effective, targeted, and less-toxic treatments.

Mueller, who earned his PhD in Cell and Molecular Biology from Baylor College of Medicine, calls SEngine's technology, "Absolutely brilliant." He says, "SEngine has developed a platform technology that can both tailor individualized treatments for cancer patients as well as identify new targets for developing better targeted cancer therapies."



Mueller worked directly with SEngine CEO Dr. Carla Grandori, in his previous role as Vice President of Industry Relation and Clinical Research Support at the Fred Hutchinson Cancer Research Center (FHCRC). Mueller says, "Dr. Grandori is well ahead of the curve with precision medicine, and pharma and biotech is starting to see the unique potential SEngine offers." SEngine recently [licensed the intellectual property](#) of more than 100 drug targets from the FHCRC. Mueller will now be instrumental to advance these targets into cancer drugs by fostering partnerships with pharmaceutical companies for clinical applications.

"Ulrich helped lead the growth of some of Seattle's most cutting edge biotech startups, driving significant equity funding, fueling hundreds of jobs and most importantly helping realize innovative cancer technology for patients," Dr. Grandori says, "He will assist in building on SEngine's strong competitive advantages."

Mueller previously served as the Managing Director of Technology Commercialization at University of Texas MD Anderson Cancer Center and held his Vice President position at Fred Hutch for nearly seven years, before joining a Houston-based biotech startup Bio-Path Holding as COO in 2014. He left Bio-Path in September of 2017 and looks forward to helping grow SEngine into a major player in the field of precision medicine.

Follow SEngine on [LinkedIn](#) and [Twitter](#) for the latest updates

**About SEngine:** Based in Seattle, Washington and founded in 2015, SEngine employs more than a dozen scientists. The biotech utilizes functional genomics and robotic testing of drugs in live patient organoids to match newly developed drugs to individual cancer patients. SEngine is a privately held company currently closing a Series A funding round. More information is available at [www.SEngineMedicine.com](http://www.SEngineMedicine.com)